Drug Type Synthetic peptide |
Synonyms- |
Target |
Mechanism API5 inhibitors(apoptosis inhibitor 5 inhibitors), PAK1 inhibitors(PAK protein kinase inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization Jalon TherapeuticsStartup |
Active Organization Jalon TherapeuticsStartup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Lymphoblastic Leukemia | Preclinical | FR | Jalon TherapeuticsStartup | 16 Apr 2023 |
Acute Promyelocytic Leukemia | Preclinical | FR | Jalon TherapeuticsStartup | 16 Apr 2023 |
Adult Acute Myeloblastic Leukemia | Preclinical | FR | Jalon TherapeuticsStartup | 16 Apr 2023 |
Sezary Syndrome | Preclinical | FR | Jalon TherapeuticsStartup | 16 Apr 2023 |